Elucidation of the mechanism of action of anti-RANKL antibody for treatment of metabolic bone disease.

Research Project

Project/Area Number	23592204
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Orthopaedic surgery
Research Institution	The University of Tokyo
Principal Investigator	MORIZAKI Yutaka 東京大学, 医学部附属病院, 助教 (30508099)
Co-Investigator(Kenkyū-buntansha)	TANAKA Sakae 東京大学, 医学部附属病院, 教授 (50282661) MIURA Toshiki 東京大学, 医学部附属病院, その他 (20376479) KADONO Yuho 東京大学, 医学部附属病院, 講師 (70401065)
Project Period (FY)	2011 – 2013
Project Status	Completed (Fiscal Year 2013)
Budget Amount *help	¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000) Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2011: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Keywords	骨・軟骨代謝学
Research Abstract	Anti-RANKL antibody is one of the most successful therapeutics for osteoporosis. The aim of this study was to elucidate the effect of the individual and combined effects of PTH and anti-RANKL monoclonal antibody in ovariectomized mice. This study suggest that co-treatment PTH with anti-RANKL antibody may make additive effect in BMD and the possibility of difference in optimal duration and effective regions.

Report

(4 results)